322 related articles for article (PubMed ID: 17916354)
1. Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.
Mandel RJ; Burger C; Snyder RO
Exp Neurol; 2008 Jan; 209(1):58-71. PubMed ID: 17916354
[TBL] [Abstract][Full Text] [Related]
2. Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease.
Bowers WJ; Howard DF; Federoff HJ
Exp Neurol; 1997 Mar; 144(1):58-68. PubMed ID: 9126153
[TBL] [Abstract][Full Text] [Related]
3. Adeno-associated viral vectors for clinical gene transfer studies.
Snyder RO; Francis J
Curr Gene Ther; 2005 Jun; 5(3):311-21. PubMed ID: 15975008
[TBL] [Abstract][Full Text] [Related]
4. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
[TBL] [Abstract][Full Text] [Related]
5. Viral vectors in the treatment of Parkinson's disease.
Latchman DS; Coffin RS
Mov Disord; 2000 Jan; 15(1):9-17. PubMed ID: 10634236
[TBL] [Abstract][Full Text] [Related]
6. Viral vectors for gene therapy in Parkinson's disease.
Latchman DS; Coffin RS
Rev Neurosci; 2001; 12(1):69-78. PubMed ID: 11236066
[TBL] [Abstract][Full Text] [Related]
7. Helper virus-free herpes simplex virus-1 plasmid vectors for gene therapy of Parkinson's disease and other neurological disorders.
Geller AI; Yu L; Wang Y; Fraefel C
Exp Neurol; 1997 Mar; 144(1):98-102. PubMed ID: 9126158
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease.
Palfi S; Gurruchaga JM; Lepetit H; Howard K; Ralph GS; Mason S; Gouello G; Domenech P; Buttery PC; Hantraye P; Tuckwell NJ; Barker RA; Mitrophanous KA
Hum Gene Ther Clin Dev; 2018 Sep; 29(3):148-155. PubMed ID: 30156440
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors.
Muramatsu S; Tsukada H; Nakano I; Ozawa K
Expert Opin Biol Ther; 2005 May; 5(5):663-71. PubMed ID: 15934841
[TBL] [Abstract][Full Text] [Related]
10. Viral vectors for gene transfer: a review of their use in the treatment of human diseases.
Walther W; Stein U
Drugs; 2000 Aug; 60(2):249-71. PubMed ID: 10983732
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease: gene therapies.
Coune PG; Schneider BL; Aebischer P
Cold Spring Harb Perspect Med; 2012 Apr; 2(4):a009431. PubMed ID: 22474617
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Value of Adeno Associated Virus as a Gene Therapy Vector for Parkinson's Disease - A Focused Review.
Singh A; Sen D
Curr Gene Ther; 2016; 16(4):278-286. PubMed ID: 27487991
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease.
Sun M; Kong L; Wang X; Holmes C; Gao Q; Zhang GR; Pfeilschifter J; Goldstein DS; Geller AI
Hum Gene Ther; 2004 Dec; 15(12):1177-96. PubMed ID: 15684695
[TBL] [Abstract][Full Text] [Related]
14. In vivo adenovirus-mediated gene transfer for Parkinson's disease.
Horellou P; Bilang-Bleuel A; Mallet J
Neurobiol Dis; 1997; 4(3-4):280-7. PubMed ID: 9361305
[TBL] [Abstract][Full Text] [Related]
15. Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.
Kelly MJ; O'Keeffe GW; Sullivan AM
Expert Rev Mol Med; 2015 May; 17():e8. PubMed ID: 25997719
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy in Parkinson's disease: rationale and current status.
Feng LR; Maguire-Zeiss KA
CNS Drugs; 2010 Mar; 24(3):177-92. PubMed ID: 20155994
[TBL] [Abstract][Full Text] [Related]
17. Viral vectors as a tool to model and treat Parkinson's disease.
Bensadoun JC; Aebischer P
Wien Klin Wochenschr; 2006 Oct; 118(19-20):568-70. PubMed ID: 17136329
[No Abstract] [Full Text] [Related]
18. Brain-targeted delivery of neuroprotective survival gene minimizing hematopoietic cell contamination: implications for Parkinson's disease treatment.
Lee MH; Kang S; Um KH; Lee SW; Hwang H; Baek K; Choi JW
J Transl Med; 2024 Jan; 22(1):53. PubMed ID: 38218903
[TBL] [Abstract][Full Text] [Related]
19. Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications.
Wong LF; Goodhead L; Prat C; Mitrophanous KA; Kingsman SM; Mazarakis ND
Hum Gene Ther; 2006 Jan; 17(1):1-9. PubMed ID: 16409120
[TBL] [Abstract][Full Text] [Related]
20. Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease.
Fischer DL; Gombash SE; Kemp CJ; Manfredsson FP; Polinski NK; Duffy MF; Sortwell CE
Methods Mol Biol; 2016; 1382():367-82. PubMed ID: 26611600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
